Crizotinib
Sign in to save this workspacePrimary targets: ALK, ROS_ROS1 · FDA status: FDA Approved
Selectivity scorecard
KISS
91.39
Gini
0.581
CATDS
0.009
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Crizotinib. Strongest target: EPHA6 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | EPHA6 | 100.0% | 0.0% |
| 2 | ROS_ROS1 | 100.0% | 0.0% |
| 3 | RON_MST1R | 99.8% | 0.2% |
| 4 | LIMK1 | 98.9% | 1.1% |
| 5 | JAK2 | 98.7% | 1.3% |
| 6 | TRKB | 98.5% | 1.5% |
| 7 | TYK1_LTK | 98.3% | 1.7% |
| 8 | HPK1_MAP4K1 | 97.9% | 2.1% |
| 9 | ALK | 97.7% | 2.3% |
| 10 | MUSK | 97.7% | 2.3% |
| 11 | TRKC | 97.3% | 2.7% |
| 12 | AXL | 97.1% | 2.9% |
| 13 | ABL1 | 97.0% | 3.0% |
| 14 | LCK | 96.8% | 3.2% |
| 15 | EPHB1 | 96.8% | 3.2% |
| 16 | C_MET | 96.7% | 3.3% |
| 17 | ARK5_NUAK1 | 96.4% | 3.6% |
| 18 | EPHA2 | 96.0% | 4.0% |
| 19 | TRKA | 95.8% | 4.2% |
| 20 | FAK_PTK2 | 95.7% | 4.3% |
Selectivity landscape
Where Crizotinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Crizotinib.
Atlas insights for Crizotinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.835 |
| SRR23303752 | — | 0.831 |
| SRR10899984 | — | 0.826 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.818 |
| aMVAC.P_005_TURBT_S223 | — | 0.816 |
Annotations
Sign in to read and post annotations.
Loading…